Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 3
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Drug: Investigator's choice of Chemotherapy
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT04342936
- Locations
- 🇨🇳
Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 550
- Registration Number
- NCT04342910
- Locations
- 🇨🇳
Affiliated Hospital, Academy of Military Medical Sciences, Beijing, China
A Food Effect Study of Apatinib Mesylate in Healthy Subjects
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04341090
- Locations
- 🇨🇳
Beijing Luhe Hospital, Capital Medical University, Beijing, Beijing, China
Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04341077
A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
Phase 3
Terminated
- Conditions
- Triple Negative Breast CancerBreast Cancer
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04335006
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04335266
- Locations
- 🇨🇳
Henan Cancer Hospital, Henan, China
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 566
- Registration Number
- NCT04333771
- Locations
- 🇨🇳
Liuzhou workers' Hospital, Liuzhou, Guangxi, China
A Study to Compare Pharmacokinetic and Safety Profiles of Different Formulations of SHR-1314 After Subcutaneous Injection in Healthy Subjects
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04326881
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04322552
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
A Study of SHR0410 in Hemodialysis Patients With Pruritus
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2020-05-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04317209
- Locations
- 🇨🇳
The first affiliated hospital of sun yat-sen university, Guangzhou, China
© Copyright 2025. All Rights Reserved by MedPath